Thailand. These health care personnel experienced fever, myalgia, centrifugal arthralgias, and injection site erythema. A history of allergic reactions to food or drugs (adjusted odds ratio, 5.9; 95% confidence interval, 1.54-25.4) was independently associated with a serum sickness-like reaction.
We report the case identification of and risk factor assessment for 14 health care personnel (HCP) who reported fever, malaise, myalgia, centrifugal arthalgias, and injection site erythema after receipt of an inactivated influenza vaccine.
Methods. Thammasat University Hospital in central Thailand is a 450-bed tertiary care university hospital that employed 985 HCP during the 3-month study period (May-July). A free annual influenza vaccination of HCP began in June 2007. During 2007 and 2008, the available influenza vaccines included 1200 doses (600 doses per year) of a trivalent inactivated virus vaccine manufactured by the Government Pharmaceutical Organisation-Merieux Biological Product (GPO-MBP) in Chachoengsao Province, Thailand (hereafter referred to as the GPO-MBP vaccine), and 100 doses (50 doses per year) of a trivalent inactivated virus vaccine manufactured by GlaxoSmithKline in Dresden, Germany (hereafter referred to as Fluarix) [6, 7] . The GPO-MBP and Fluarix vaccine formulations and virus strains were identical and consistent with World Health Organization recommendations for the Southern Hemisphere influenza vaccine [8] . The vaccination program, coordinated by the hospital's infection control team, targeted 550 HCP in the emergency department, intensive care units, internal medicine units, and surgical units. After an infectious diseases physician (A.A.) at Thammasat University Hospital received reports that HCP were having a serum sickness-like reaction to influenza vaccination, an investigation was initiated during the period from 1 June 2008 through 31 October 2008. By 14 August 2009, there were 14 HCP who were identified as having a serum sickness-like reaction. A case of serum sickness-like reaction was defined as occurring in a patient who developed fever, myalgia, centrifugal arthralgias, and injection site erythema within the 3-28-day interval after influenza vaccination. Both active surveillance for potential cases of serum sickness-like reaction and a review of the medical records of HCP were conducted. Cases were excluded if there was a diagnosis of anaphylaxis, systemic lupus erythomatosus, periarteritis nodosa, or drug hypersensitivity. (table 2) . Their symptoms started with erythema at the injection site, followed by pain, induration, centrifugal arthalgias, fever, and malaise; all symptoms were resolved without absenteeism or hospitalization. The median duration from vaccination to onset of serum Facial edema 1 In multivariable analysis, a history of allergic reactions to food or drugs (adjusted odds ratio, 5.9; 95% confidence interval, 1.54-25.4;
) was the only independent risk factor as-P p .005 sociated with serum sickness-like reaction among HCP who received the GPO-MBP vaccine in 2007 and 2008. All 14 HCP received treatment: 8 (57%) received acetaminophen, 6 (43%) received nonsteroidal medications, and none required hospitalization. One HCP (7%) developed a diffuse pruritic cutaneous eruption that required a 7-day course of oral corticosteroid treatment. For these 14 HCP, the median duration of reported symptoms of serum sickness-like reaction was 6 days (range, 4-14 days), and all recovered without further sequelae.
Discussion. We retrospectively identified 14 (3%) of 495 HCP who had a serum sickness-like reaction after receiving their second dose of inactivated influenza vaccine in 2008. Of note, the incidence, duration from exposure to onset, and severity of illness among these 14 HCP were different from those among the cases of possible serum sickness-like reaction reported to the US Vaccine Adverse Event Reporting System (VAERS) [10] , a national surveillance system cosponsored by the US Food and Drug Administration and the Centers for Disease Control and Prevention that collects information about adverse events that occur after the administration of US-licensed vaccines. Since 1991, 1800 million doses of trivalent inactivated virus vaccine have been distributed in the United States. As of December 2008, only 45 unconfounded reports (i.e., no concomitant vaccine administered) of possible serum sickness after receipt of a trivalent inactivated virus vaccine were submitted to the VAERS. After receipt of the second dose of influenza vaccine, the median duration from vaccination to onset of serum sickness-like reaction among these 14 Thai HCP was 9 days, which is within previous estimates of 7-21 days after primary exposure and 1-4 days after secondary exposure but is substantially longer than the 24-h interval reported to VAERS for 150% of US cases of possible serum sickness after receipt of a trivalent inactivated virus vaccine. Finally, the 14 cases of serum sickness-like reaction reported in our study were characterized as mild-to-moderate illness with full recovery, compared with reports of serum sickness-like reaction being a potentially life-threatening illness [1] [2] [3] . It is notable that none of the 14 HCP who had a serum sickness-like reaction reported having red eyes, facial edema associated with oculorespiratory syndrome, or any respiratory symptoms after receipt of the GPO-MBP vaccine [11, 12] .
Recognized risk factors associated with a serum sicknesslike reaction include receipt of a drug or antitoxin known to cause serum sickness and receipt of high quantities of snake venom antiserum, horse serum, or rabies immunoglobulin [1] [2] [3] 13] . In the study by Suwansrinon et al. [13] , female sex and an age of 110 years were associated with a serum sickness-like reaction after administration of rabies immunoglobulin. Other investigations have reported that atopy and an allergic reaction to antibiotics and anesthetic agents were risk factors for serum sickness-like reaction among women [13, 14] . In our study, a history of allergic reactions to food or drugs was the sole predictor of a serum sickness-like reaction. Whether there is an association between prior allergic reactions, estrogen or testosterone levels, and autoimmunity will require further investigation.
Our study had several limitations. First, no causality of trivalent inactivated virus vaccine to serum sickness-like reaction can be made. Our study design was retrospective, and few data exist that show an association of serum sickness-like reaction with trivalent inactivated virus vaccine. Second, laboratory data were available for only 8 (57%) of the 14 HCP who sought medical care. However, these 8 HCP had leukopenia, thrombocytopenia, and low C3 and C4 levels, suggesting moderately severe reactions. Third, the small sample size limited our ability to evaluate other potential risk factors associated with serum sickness-like reaction. Fourth, we cannot exclude the possibility that a serum sickness-like reaction had no relationship to the influenza vaccination in 2007 but was only associated with the receipt of the GPO-MBP vaccine in 2008, because we did not study HCP who only received a trivalent inactivated virus vaccine in 2008. Finally, because permission was not obtained to investigate serum sickness-like reactions after vaccination in other hospitals, we were not able to determine the overall incidence of serum sickness-like reaction among HCP or to distinguish whether the incidence was associated with a host or vaccine-specific factor.
In conclusion, clinicians should be aware of the potential for a serum sickness-like reaction after administration of inactivated influenza vaccine. Further investigations are needed to assess the risk of a serum sickness-like reaction after administration of a trivalent inactivated virus vaccine over multiple years, including persons with food or drug allergies, to determine whether our findings apply to other influenza vaccines or only to the 2008 GPO-MBP vaccine. Because influenza vaccination is recommended for all Thai HCP, our findings support prioritizing the establishment of a Thai national VAERS-like program, along with enhanced infrastructure for occupational health and safety programs throughout the country.
